Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Leukemia, B-Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1Blood Protein Disorders 1

Interventions

Rituximab 4Cyclophosphamide 4ponatinib 2Vorinostat 2Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bortezomib 2tetulomab tetraxetan lu-177 1pembrolizumab 1ibrutinib 1ibritumomab tiuxetan 1fludarabine 1durvalumab 1cobomarsen 1acalabrutinib 1Melphalan 1Lutetium 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Ifosfamide 1Hsp90 inhibitor KU757 1Cytarabine 1Carmustine 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Immune System Diseases × Hsp90 inhibitor KU757 × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡